Usistapide

Drug Profile

Usistapide

Alternative Names: JNJ-16269110; JNJ1629110; R-256918

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Acetic acids; Amides; Antihyperglycaemics; Obesity therapies; Piperidines; Small molecules
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 11 Feb 2010 Safety and pharmacokinetics data from a phase I study in volunteers released by Johnson and Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top